NCT03925818

Low Dose Bismuth Versus Lactobacillus Reuteri for H. Pylori Eradication

Twice-a-day PPI, Tetracycline, Metronidazolequadruple Therapy With Pylera® or Lactobacillus Reuteri for Treatment naïve or for Retreatment of H. Pylori: Two Randomized Pilot Studies

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 99 (actual)
• Sponsor: Università degli Studi di Sassari · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study investigates the efficacy of a b.i.d. quadruple therapy containing Pylera® or L. reuteri for H. pylori infection.

Detailed description

Bismuth, metronidazole and tetracycline yielded high cure rates for H. pylori infection. Earlier studies suggested that the bismuth quadruple therapy may be effective when given twice-a-day rather than q.i.d. and that b.i.d. therapy was associated with fewer side effects. The addition of the probiotic Lactobacillus reuteri (Gastrus®) to Lactobacillus reuteri (Gastrus®) that has been shown to increase the cure rates by 10-14%. In another study bismuth supplementation with L. reuteri DSM 17938, in a modified low dose quadruple therapy provided good eradication rates (93.3%; 95% CI : 85-99%) in clinical practice.

Conditions

• Helicobacter Pylori Infection

Interventions

Type	Name	Description
DRUG	Bismuth Subcitrate Potassium	Pylera capsules
DIETARY_SUPPLEMENT	Gastrus	Gastrus 1 tablet

Timeline

• Start date: 2017-08-29
• Primary completion: 2018-11-29
• Completion: 2018-12-23
• First posted: 2019-04-24
• Last updated: 2019-04-26

Locations

1 site across 1 country: Italy